tirofiban has been researched along with Disease Models, Animal in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Adair, BD; Ahn, HS; Alonso, JL; Arnaout, MA; Hayes, V; Lin, SW; Poncz, M; van Agthoven, J; Xiong, JP; Yu, IS | 1 |
| He, B; Qiao, ZQ; Shen, XD; Xu, TY; Zhao, H | 1 |
| Kingma, JG | 1 |
| Eric Wang, W; Guan, W; Han, Y; Liu, Y; Ren, H; Wang, Z; Yang, J; Zeng, C; Zhou, L | 1 |
| Djorgoski, I; Janevik-Ivanovska, E; Serafimovska, MD; Ugresic, M | 1 |
| Cao, Y; Ding, X; Gamariel, RR; Kong, Y; Li, ZY; Liu, TD; Liu, XD; Ming, X; Wang, CH; Xie, ZL; Zhao, Q | 1 |
| Chamorro, A; Díez-Marqués, ML; Griera, M; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Ruiz-Torres, MP | 1 |
| Dziegielewski, P; Fu Zhu, L; Harris, J; Seikaly, H; Singh, P | 1 |
| Cheng, CF; Cheng, WT; Kikuchi, T; Lian, WS; Lin, H | 1 |
| Alame, G; Cazenave, JP; Freund, M; Gachet, C; Gaertner, S; Hechler, B; Leguay, C; Petitou, M | 1 |
| Badenhorst, PN; Lamprecht, S; Meiring, SM; Roodt, JP; van Rensburg, WJ | 1 |
| Bock, A; Leitsch, T; Schimmer, M; Schultheiss, HP; Seligmann, C; Simsek, Y | 1 |
| Azarbal, B; Cercek, B; Finkelstein, A; Kaul, S; Rukshin, V; Shah, PK; Tsang, V | 1 |
| Aoki, T; Maeda, M; Matsuoka, N; Mihara, K; Moriguchi, A; Mutoh, S | 1 |
| Coull, BM; McDonagh, PF; Ritter, LS; Stempel, KM | 1 |
| Concannon, MJ; Farias, CL; Kazmier, FR; Puckett, CL; Yates, YJ | 1 |
| Emiroglu, M; Gulmez, SE; Heper, AO; Kaya, B; Serel, S | 1 |
18 other study(ies) available for tirofiban and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis.
Topics: Animals; Blood Coagulation; Disease Models, Animal; Drug Design; Gene Knock-In Techniques; Healthy Volunteers; Hemorrhage; Humans; K562 Cells; Male; Mice; Mice, Transgenic; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Structure-Activity Relationship; Thrombosis; Tirofiban; von Willebrand Factor | 2020 |
Combined use of external therapeutic ultrasound and tirofiban has synergistic therapeutic effects on no-reflow after myocardial reperfusion.
Topics: Acute Disease; Animals; Combined Modality Therapy; Disease Models, Animal; Dogs; Fibrinolytic Agents; Male; Myocardial Infarction; Myocardial Reperfusion; Tirofiban; Ultrasonic Therapy | 2018 |
Effect of Platelet GPIIb/IIIa Receptor Blockade With MK383 on Infarct Size and Myocardial Blood Flow in a Canine Reocclusion Model.
Topics: Animals; Blood Platelets; Disease Models, Animal; Dogs; Female; Male; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quebec; Tirofiban; Treatment Outcome | 2019 |
Protective effects of tirofiban on ischemia/reperfusion-induced renal injury in vivo and in vitro.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Blood Urea Nitrogen; Cell Line; Chemotaxis, Leukocyte; Creatinine; Cytoprotection; Disease Models, Animal; Kidney; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Reperfusion Injury; Tirofiban; Tyrosine | 2015 |
Imaging of deep venous thrombosis using radioactive-labeled tirofiban.
Topics: Animals; Disease Models, Animal; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Radionuclide Imaging; Rats; Rats, Wistar; Technetium; Tirofiban; Tyrosine; Venous Thrombosis | 2015 |
A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin
Topics: Abciximab; Animals; Antibodies, Monoclonal; Cardiovascular Diseases; Disease Models, Animal; Eptifibatide; Fibrinogen; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Integrin alpha2; Integrin beta3; Mice; Naphthalenes; Peptides; Platelet Aggregation; Rats; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2016 |
Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Guanylate Cyclase; Humans; Hypertension; Isosorbide Dinitrate; Male; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Tachyphylaxis; Time Factors; Tirofiban; Tyrosine; Up-Regulation; Vasodilation; Vasodilator Agents | 2009 |
Heparin versus tirofiban in microvascular anastomosis: randomized controlled trial in a rat model.
Topics: Anastomosis, Surgical; Animals; Disease Models, Animal; Drug Therapy, Combination; Fascia; Fibrinolytic Agents; Follow-Up Studies; Free Tissue Flaps; Head and Neck Neoplasms; Heparin; Microsurgery; Neoplasms, Experimental; Plastic Surgery Procedures; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Rats; Rats, Sprague-Dawley; Skin Transplantation; Therapeutic Irrigation; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine; Wound Healing | 2011 |
Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Fibrosis; Granulocyte Colony-Stimulating Factor; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Macrophages; Male; Mice; Mice, Inbred C57BL; Myocarditis; Simvastatin; Thrombosis; Tirofiban; Tyrosine | 2011 |
The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
Topics: Animals; Biotin; Disease Models, Animal; Drug Combinations; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligosaccharides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thromboembolism; Tirofiban; Tyrosine | 2011 |
Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Anticoagulants; Disease Models, Animal; Immunoglobulin Fab Fragments; Primates; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Human thrombocytes are able to induce a myocardial dysfunction in the ischemic and reperfused guinea pig heart mediated by free radicals-role of the GPIIb/IIIa-blocker tirofiban.
Topics: Animals; Blood Platelets; Cardiac Output; Disease Models, Animal; Fibrinolytic Agents; Guinea Pigs; Humans; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Superoxide Dismutase; Tirofiban; Tyrosine | 2002 |
Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2003 |
FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
Topics: Animals; Blood Platelets; Brain; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Infarction, Middle Cerebral Artery; Intracranial Thrombosis; Male; Microcirculation; Neutrophils; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propionates; Recovery of Function; Reperfusion Injury; Tirofiban; Tyrosine | 2005 |
Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion.
Topics: Analysis of Variance; Animals; Anticoagulants; Biomarkers; Blood Platelets; Brain Ischemia; Disease Models, Animal; Flow Cytometry; Inflammation; Leukocytes; Male; Myocardial Reperfusion Injury; Neutrophil Activation; Neutrophils; Platelet Aggregation; Platelet Aggregation Inhibitors; Polysaccharides; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Severity of Illness Index; Stroke; Time Factors; Tirofiban; Tyrosine | 2005 |
The effect of tirofiban on microvascular thrombosis: crush model.
Topics: Anastomosis, Surgical; Animals; Disease Models, Animal; Femoral Artery; Isotonic Solutions; Microsurgery; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Random Allocation; Rats; Rats, Sprague-Dawley; Ringer's Lactate; Thrombosis; Tirofiban; Tyrosine; Vascular Patency | 2005 |
Effect of platelet glycoprotein IIb/IIIa receptor antagonist on survival of epigastric island flaps in rats with total venous occlusions.
Topics: Abdominal Wall; Animals; Disease Models, Animal; Graft Survival; Laser-Doppler Flowmetry; Male; Necrosis; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Surgical Flaps; Tirofiban; Tyrosine; Venous Insufficiency | 2008 |